Arkolith/Insider Trading/CHRS/Form 4

Wahlstrom Mats

DirectorCoherus BioSciences, Inc. (CHRS) · full profile →Form 4 · filed Feb 5, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
2 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 1, 2024Option exercise(M)15K$1.67$25K55K
Feb 1, 2024Option exercise(M)45K$1.67$75K100K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 1, 2024Option exercise(M)45K—$00
Feb 1, 2024Option exercise(M)15K—$00

Transaction Codes

M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001610717-24-000044) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML